482 related articles for article (PubMed ID: 17018563)
1. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
Drudy D; Quinn T; O'Mahony R; Kyne L; O'Gaora P; Fanning S
J Antimicrob Chemother; 2006 Dec; 58(6):1264-7. PubMed ID: 17018563
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates.
Walkty A; Boyd DA; Gravel D; Hutchinson J; McGeer A; Moore D; Simor A; Suh K; Taylor G; Miller M; Mulvey MR;
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):419-24. PubMed ID: 20226332
[TBL] [Abstract][Full Text] [Related]
3. Diversity of moxifloxacin resistance during a nosocomial outbreak of a predominantly ribotype ARU 027 Clostridium difficile diarrhea.
Carman RJ; Genheimer CW; Rafii F; Park M; Hiltonsmith MF; Lyerly DM
Anaerobe; 2009 Dec; 15(6):244-8. PubMed ID: 19818865
[TBL] [Abstract][Full Text] [Related]
4. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.
Ackermann G; Tang YJ; Kueper R; Heisig P; Rodloff AC; Silva J; Cohen SH
Antimicrob Agents Chemother; 2001 Aug; 45(8):2348-53. PubMed ID: 11451695
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
Spigaglia P; Barbanti F; Louie T; Barbut F; Mastrantonio P
Antimicrob Agents Chemother; 2009 Jun; 53(6):2463-8. PubMed ID: 19364867
[TBL] [Abstract][Full Text] [Related]
6. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
7. PCR ribotype prevalence and molecular basis of macrolide-lincosamide-streptogramin B (MLSB) and fluoroquinolone resistance in Irish clinical Clostridium difficile isolates.
Solomon K; Fanning S; McDermott S; Murray S; Scott L; Martin A; Skally M; Burns K; Kuijper E; Fitzpatrick F; Fenelon L; Kyne L
J Antimicrob Chemother; 2011 Sep; 66(9):1976-82. PubMed ID: 21712239
[TBL] [Abstract][Full Text] [Related]
8. Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes.
Huang H; Wu S; Wang M; Zhang Y; Fang H; Palmgren AC; Weintraub A; Nord CE
Int J Antimicrob Agents; 2009 Apr; 33(4):339-42. PubMed ID: 19097757
[TBL] [Abstract][Full Text] [Related]
9. In vitro development of resistance to DX-619 and other quinolones in enterococci.
Wickman PA; Black JA; Smith Moland E; Thomson KS; Hanson ND
J Antimicrob Chemother; 2006 Dec; 58(6):1268-73. PubMed ID: 17062613
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of susceptibility to fluoroquinolones in Bartonella isolates from Australia reveals a natural mutation in gyrA.
Angelakis E; Biswas S; Taylor C; Raoult D; Rolain JM
J Antimicrob Chemother; 2008 Jun; 61(6):1252-5. PubMed ID: 18334491
[TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe.
Spigaglia P; Barbanti F; Mastrantonio P; Brazier JS; Barbut F; Delmée M; Kuijper E; R Poxton I; On Behalf Of The European Study Group On Esgcd
J Med Microbiol; 2008 Jun; 57(Pt 6):784-789. PubMed ID: 18480338
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
[TBL] [Abstract][Full Text] [Related]
13. The characteristics of Clostridium difficile ST81, a new PCR ribotype of toxin A- B+ strain with high-level fluoroquinolones resistance and higher sporulation ability than ST37/PCR ribotype 017.
Wang B; Peng W; Zhang P; Su J
FEMS Microbiol Lett; 2018 Sep; 365(17):. PubMed ID: 30085003
[TBL] [Abstract][Full Text] [Related]
14. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile.
Drudy D; Harnedy N; Fanning S; Hannan M; Kyne L
Infect Control Hosp Epidemiol; 2007 Aug; 28(8):932-40. PubMed ID: 17620240
[TBL] [Abstract][Full Text] [Related]
15. Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB.
Rimbara E; Noguchi N; Kawai T; Sasatsu M
Helicobacter; 2012 Feb; 17(1):36-42. PubMed ID: 22221614
[TBL] [Abstract][Full Text] [Related]
16. Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacin.
De Azavedo JC; Duncan CL; Kilburn L; Downar J; Kong B; Lad S; Low DE; Bast DJ
J Chemother; 2006 Aug; 18(4):373-8. PubMed ID: 17024792
[TBL] [Abstract][Full Text] [Related]
17. Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
Saxton K; Baines SD; Freeman J; O'Connor R; Wilcox MH
Antimicrob Agents Chemother; 2009 Feb; 53(2):412-20. PubMed ID: 18710908
[TBL] [Abstract][Full Text] [Related]
18. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC
J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926
[TBL] [Abstract][Full Text] [Related]
19. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients.
Kim JM; Kim JS; Kim N; Jung HC; Song IS
J Antimicrob Chemother; 2005 Nov; 56(5):965-7. PubMed ID: 16159928
[TBL] [Abstract][Full Text] [Related]
20. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
Lázaro FG; Rodríguez-Tarazona RE; García-Rodríguez JA; Muñoz-Bellido JL
Int J Antimicrob Agents; 2009 Sep; 34(3):252-4. PubMed ID: 19243922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]